These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 4275111)
1. Pathophysiology of drug-induced dyskinesias. Korczyn AD Neuropharmacology; 1972 Sep; 11(5):601-7. PubMed ID: 4275111 [No Abstract] [Full Text] [Related]
2. The neuropharmacology of abnormal involuntary movement disorders (the dyskinesias). Marsden CD Mod Trends Neurol; 1975; 6():141-66. PubMed ID: 127927 [No Abstract] [Full Text] [Related]
3. Dopamine in the basal ganglia. Its role and therapeutic implications (including the clinical use of L-DOPA). Hornykiewicz O Br Med Bull; 1973 May; 29(2):172-8. PubMed ID: 4356552 [No Abstract] [Full Text] [Related]
4. Parkinson's disease: from brain homogenate to treatment. Hornykiewicz O Fed Proc; 1973 Feb; 32(2):183-90. PubMed ID: 4143953 [No Abstract] [Full Text] [Related]
6. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. Bernheimer H; Birkmayer W; Hornykiewicz O; Jellinger K; Seitelberger F J Neurol Sci; 1973 Dec; 20(4):415-55. PubMed ID: 4272516 [No Abstract] [Full Text] [Related]
7. [Dopamine and the parkinsonism-chorea antagonism]. Bulandra R; Serbanesco A Rev Neurol (Paris); 1972 Aug; 127(2):315. PubMed ID: 4147105 [No Abstract] [Full Text] [Related]
8. [10 years of L-DOPA therapy of Parkinson's syndrome]. Birkmayer W Wien Klin Wochenschr; 1971 Apr; 83(13):221-7. PubMed ID: 4254333 [No Abstract] [Full Text] [Related]
9. The biochemistry of dyskinesias. Curzon G Int Rev Neurobiol; 1967; 10():323-70. PubMed ID: 4230017 [No Abstract] [Full Text] [Related]
11. The modification of L-dopa induced dyskinesias in the monkey by unilateral nigral lesions. Mones RJ; Pasik P; Pasik T; Wilk S Trans Am Neurol Assoc; 1973; 98():234-7. PubMed ID: 4206371 [No Abstract] [Full Text] [Related]
15. Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism. Brogden RN; Speight TM; Avery GS Drugs; 1971; 2(4):262-400. PubMed ID: 4340597 [No Abstract] [Full Text] [Related]